S. Hamann

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

G. Folprecht, T. Trarbach, G. Ehninger, 2014, BMC Cancer.

PC‐SPES, a dietary supplement for the treatment of hormone‐refractory prostate cancer

S. Hamann, K. Klippel, B. Pfeifer, 2000, BJU international.

Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia

G. Ehninger, M. Schaich, N. Gökbuget, 2010, Annals of Hematology.

Preoperative high-dose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study.

P. Neuhaus, C. Höflich, J. Langrehr, 2007, Journal of hepato-biliary-pancreatic surgery.

Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.

G. Folprecht, G. Poston, H. Malik, 2014, European journal of cancer.

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

C. Köhne, G. Folprecht, D. Strumberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.

G. Folprecht, D. Strumberg, U. Hacker, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer

C. Köhne, G. Folprecht, D. Strumberg, 2011 .